Sign in

NCT07631923Not yet recruiting

Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis

Acute Intermittent Hypoxia (AIH) Primed Myoelectric Interface Neurorehabilitation Training (MINT) for Gait Recovery in Multiple Sclerosis

Source: ClinicalTrials.gov · Last updated 8 Jun 2026

Brief summary (registry, in English)

This interventional, randomized, sham-controlled study will examine whether Acute Intermittent Hypoxia (AIH) delivered immediately before Myoelectric Interface Neurorehabilitation Training (MINT)-based locomotor training improves gait in people with Multiple Sclerosis. The primary objectives are to evaluate changes in gait speed and endurance, with secondary objectives assessing spatiotemporal gait parameters, fatigue, and safety. Participants will receive AIH or sham priming followed by standardized treadmill and/or overground gait training, with outcome measures collected before and after the intervention across multiple sessions.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
35 (estimated)
First submitted
2 Jun 2026
Start date
15 Jun 2026
Primary completion date
1 Jan 2028
Lead sponsor
Shirley Ryan AbilityLab
NCT number
NCT07631923

What you commit to

  • Study type: Interventional
  • Planned participants: 35
  • From 15 Jun 2026 to the primary completion date, 1 Jan 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Uncontrolled hypertension or hypotension outside the required ranges
  • History of epilepsy or seizures
  • Uncontrolled pulmonary, cardiovascular, or orthopedic disease
  • Premorbid or ongoing major psychiatric illness (e.g., major depression, psychosis)
  • Other neurological disease (e.g., stroke, traumatic brain injury, peripheral neuropathy)
  • Illnesses with potential to cause brain injury

Other

  • Frequent or severe unexplained headaches
  • Pregnancy
  • Implanted medical devices (e.g., pacemakers, intrathecal pumps, brain stimulators)

Who the study is looking for

  • Diagnosis of clinically definite multiple sclerosis
  • Patient-Determined Disease Steps (PDDS) score between 3 and 6
  • Relapse-free for at least 6 months prior to enrollment
  • Age ≥ 18 years and ≤ 75 years
  • Resting oxygen saturation (SpO₂) ≥ 95% on room air
  • Systolic blood pressure between 85-140 mmHg and diastolic blood pressure between 55-90 mmHg
  • Modified Ashworth Scale (MAS) score ≤ 3 at the ankle and knee
  • Mini-Mental State Examination (MMSE) score ≥ 24
  • Ability to walk at least 10 meters with or without an assistive device
  • Ability to perform active ankle dorsiflexion and plantarflexion

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.